title: Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
abstract: Despite survival gains achieved nearly two decades ago with combination platinum- and taxane-based intravenous chemotherapy, overall survival curves have remained relatively unchanged during the 21st century using newer cytotoxic agents. Although combined intravenous-intraperitoneal (IV-IP) chemotherapy is promising, tolerability remains a significant issue. An emphasis has been placed on exploring dose dense schedules and targeted agents. Vascular endothelial growth factor (VEGF) has emerged as an important therapeutic target in several solid tumors including ovarian carcinoma. The monoclonal antibody, bevacizumab, binds VEGF, thus preventing activation of the VEGF receptor (VEGFR) leading to inhibition of tumor angiogenesis. To date eight phase 3 randomized controlled trials incorporating anti-angiogenesis therapy in the treatment of newly diagnosed and recurrent ovarian carcinoma have met their primary endpoints. Four of these trials included bevacizumab and were reported from 2010 to 2012. During 2013, the other four studies were reported, each studying one of the following novel anti-angiogenesis agents: pazopanib, cediranib, trebananib, and nintedanib. Importantly, none of these drugs have been approved by the United States Food and Drug Administration (US FDA) for the treatment of ovarian cancer. The purpose of this review will be to highlight both VEGF-dependent and non-VEGF dependent angiogenic pathways in ovarian cancer and discuss the phase 3 experiences and regulatory implications of targeting the tumor microenviroment with anti-angiogenesis therapy.
authors: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Building 56, 101 The City Dr., Orange, CA 92868, USA. Electronic address: eskander@uci.edu.
authors: Ramez N
authors: RN
authors: Eskander
authors: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Building 56, 101 The City Dr., Orange, CA 92868, USA. Electronic address: ktewari@uci.edu.
authors: Krishnansu S
authors: KS
authors: Tewari
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006801:Humans; D009375:Neoplasms, Glandular and Epithelial / Q000098:blood supply* / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D020533:Angiogenesis Inhibitors
keywords: Angiogenesis; Bevacizumab; Cediranib; Nintedanib; Pazopanib; Trebananib